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Abstract: This paper describes the successful mobilization of peripheral blood stem cells 
for autologous transplantation in three children with malignant diseases by using plerixafor 
(Mozobil™; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor 
(G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circu-
lating CD34+ cells after plerixafor treatment as compared with the baseline level was observed. 
An optimal CD34+ cell count for transplantation with one or two leukapheresis sessions was 
achieved. Mobilization using plerixafor was found to be safe with no adverse events. Therefore, 
the combination of G-CSF and plerixafor in children results in effective increases in peripheral 
CD34+ cell counts and reduces the risk of mobilization failure.
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Introduction
High-dose chemotherapy followed by autologous peripheral blood stem cell (PBSC) 
support is a salvage treatment option for patients with relapsed or refractory malignant 
diseases such as lymphomas, multiple myeloma (MM), and solid tumors.1 The mini-
mum dose of hemopoietic stem cells necessary for a prompt and durable engraftment 
is 2 × 106 CD34+ cells/kg body weight.2 Unfortunately, this required minimum count 
is not achieved in approximately 20%–40% of patients undergoing mobilization, who 
are considered “poor mobilizers”.3 Mobilization of adequate numbers of PBSCs for 
myeloablative chemotherapy can be challenging in children and adults, although less 
frequently in the latter.4 There is limited information about the frequency of unsuc-
cessful mobilizations in children. Our experience revealed that approximately 11% of 
children and 21% of adults are poor mobilizers. Most of the children considered poor 
mobilizers either have Hodgkin’s disease (HD) and solid tumors, or received large-
volume chemotherapy and radiotherapy before attempted mobilization, or both.
Plerixafor (Mozobil™; Genzyme Corporation, Cambridge, MA) is a selective and 
reversible CXC chemokine receptor type 4 (CXCR4) antagonist and interrupts inter-
action of CXCR4 with stromal cell-derived factor-1 (SDF-1), thus resulting in rapid 
mobilization of stem cells in peripheral blood. In combination with granulocyte-colony 
stimulating factor (G-CSF), plerixafor leads to successful mobilization in approxi-
mately 70% of adult patients with non-Hodgkin’s lymphoma, HD, and MM who failed 
a previous mobilization with G-CSF alone or in combination with   chemotherapy.5 
Data on the use of plerixafor in stem cell mobilization in children are very limited.3,4,6,7 Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Therefore, the experience, although limited, of our institution 
in the use of plerixafor for PBSC mobilization in children 
with cancer is presented here.
Methods
The patients are three boys, aged 8 years (Patient 1), 17 years 
(Patient 2), and 7 years (Patient 3) (Table 1). Two patients 
have HD with extranodal localizations (lung and bone), 
and one patient has a metastatic germ cell tumor. They all 
have   refractory disease, had exhibited partial remission after 
second-line treatment, and consented to receive myeloablative 
chemotherapy and autologous PBSC transplantation as a sal-
vage therapy. All three patients failed an earlier mobilization 
with chemotherapy and G-CSF, and Patient 1 failed a second 
mobilization with G-CSF alone (CD34+ cell count below 
10 cells/µL in peripheral blood measured before apheresis). The 
patients with HD were mobilized using cyclophosphamide and 
G-CSF, and the patient with the germ cell tumor was mobilized 
using cyclophosphamide, etoposide (VP-16), and G-CSF.
After a discussion within the institution, it was decided that 
mobilization would be performed in each of these patients using 
a protocol for plerixafor and G-CSF. Plerixafor was obtained 
on a compassionate basis from Genzyme Bulgaria (Sofia). 
Written informed consent was obtained from the parents of 
the patients before therapy. Mobilization not including chemo-
therapy was started during each patient’s hematological steady 
state with a 4-day subcutaneous administration of nonpegylated 
G-CSF at 10 µg/kg once daily in the morning. In the evening 
of the fourth day, at 11 hours before apheresis, plerixafor at 
240 µg/kg was subcutaneously administered. G-CSF was given 
on the fifth day at 1 hour before apheresis. Patient 1 underwent 
one apheresis session with a very high yield of CD34+ cells, 
whereas the other two patients required two days for   collections. 
In Patients 2 and 3, the session of plerixafor was repeated. 
PBSC collections began when the circulating CD34+ cell 
count exceeded 15 cells/µL after plerixafor administration. 
Double-volume leukapheresis was performed according to 
institutional guidelines. Harvesting was performed using the 
Fresenius Kabi AG (Bad Homburg, Germany) COM.TEC 
apheresis system. Apheresis product processing and storage 
were performed as per standardized procedures. According to 
institutional guidelines, the stem cell products were tested for 
bacterial and fungal contamination but not for tumor cell con-
tamination (the protocol makes no provision for tumor cells). 
All products tested negative for microbial contamination.
Results
In all three patients, the peripheral blood CD34+ cell counts 
increased 3–13-fold (176, 31, and 75 cells/µL in Patients 1, 
2, and 3, respectively) (Figure 1) at 11 hours following first 
plerixafor application. The total number of white blood cells 
also increased but less markedly. Successful total CD34+ cell 
yields above the margin of 2 × 106 cells/kg (11.3 × 106, 
3.27 × 106, and 4.76 × 106 cells/kg) after one or two apheresis 
sessions was obtained. The patients did not experience any local 
or systemic adverse effects attributed to plerixafor such as diar-
rhea, nausea, injection site reactions, fatigue, headache, hyper-
sensitivity, muscular pain, dizziness, arthralgia, or less common 
adverse effects such as dyspnea, increased fibrin d-dimers, 
anemia, hypotension, pulmonary embolism, and spleen 
Table 1 Patient characteristics
Characteristic Patient 1 Patient 2 Patient 3
Age (years) 8 17 7
Sex Male Male Male
Body weight (kg) 25 50 33
Diagnosis HD Germ cell tumor HD
Disease status at the time of PBSC mobilization PR PR PR
Previous mobilization (n/type) 2/ch + G-CSF; G-CSF 1/ch + G-CSF 1/ch + G-CSF
Previous radiotherapy Yes No No
Number of previous chemotherapy cycles 12 8 8
Number of plerixafor injections 1 2 2
Daily dose of plerixafor (mg) 6 12 8
WBC at baseline (/µL) 42 × 103 39 × 103 24.9 × 103
WBC at 11 hours after plerixafor (/µL) 58.8 × 103 63 × 103 57.4 × 103
CD34+ at baseline (/µL) 13 11 7
CD34+ at 11 hours after plerixafor (/µL) 176 31 75
-fold – increase CD34+ count 13.5 2.8 10.7
Total number of collected CD34+ cells (×106/kg) 11.3 3.27 4.76
Total number of aphereses per patient 1 2 2
Abbreviations: Ch, chemotherapy; G-CSF, granulocyte-colony stimulating factor; HD, Hodgkin’s disease; PBSC, peripheral blood stem cell; PR, partial remission; 
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  rupture. All patients received myeloablative   chemotherapy for 
their   specific diseases followed by the infusion of collected 
CD34+ cells. Hematological recovery (absolute neutrophil 
count, .500 cells/µL; platelet count, .20,000 cells/µL) 
occurred on days 9 and 11, 11 and 15, and 10 and 13 after the 
treatment for patients 1, 2, and 3, respectively. All patients had 
no transplant-related infections or other comorbidities.
Discussion
In adults with lymphomas and MM, the success of stem 
cell mobilization induced by plerixafor and G-CSF is well 
established. Although a number of studies from different 
centers and countries have demonstrated the efficacy of this 
combination in adults, studies in children are limited.3,4,6,7 
It should be noted that most of the described children have 
solid tumors.4,6,7 This is mainly because the current treatment 
strategy in this age group involves single or tandem myeloab-
lative chemotherapy with autologous PBSC transplantation 
for relapsed or conventional chemotherapy-resistant brain 
tumors, neuroblastomas, Ewing sarcomas, germ cell tumors, 
and other malignancies. These patients are often heavily pre-
treated and have difficulties in mobilizing the minimal num-
ber of CD34+ cells for transplantation. Most of these patients 
require more than two mobilization attempts or bone marrow 
harvesting, with all its known unfavorable effects, and delays 
in the administration of high-dose chemotherapy.4
The results of the present study show that the combination 
of G-CSF and plerixafor in children results in a higher increase 
in the peripheral CD34+ cell counts, provides sufficient num-
bers of PBSCs for transplantation with fewer apheresis ses-
sions, ensures a faster progression to high-dose chemotherapy, 
and reduces the risk of mobilization failure with an acceptable 
safety profile and time periods to engraftment.3,4
Conclusion
On the basis of this report and the reviewed literature, G-CSF 
and plerixafor can be considered a suitable combination for 
PBSC mobilization in children with malignant diseases and 
failures in previous conventional mobilization attempts. 
Standard guidelines for the use of plerixafor in stem cell 
mobilization in pediatric patients based on multicenter studies 
will obviously be needed.
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Figure 1 Sharp increase of patient’s peripheral blood CD34+ cell counts 11 hours 
after the application of plerixafor (day 5, morning).
Abbreviations: HD, Hodgkin’s disease; PBSC, peripheral blood stem cell; G-CSF, 
granulocyte-colony stimulating factor; WBC, white blood cells.